Global Breast Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

Global breast cancer diagnostics market is projected to register a CAGR of 9.2% in the forecast period of 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation:

Global Breast Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centres, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, and Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Ireland, Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the global breast cancer diagnostics market are:

Increasing breast cancer patients among the women population as well as men

Rise in technological advancement for breast cancer diagnostic

Market Players

The key market players operating in the global breast cancer diagnostics market are:

F-Hoffmann La Roche Ltd.

Siemens Healthcare GmbH

General Electric

Koninklijke Philips N.V.

FUJIFILM Corporation

Abbott

Hologic, Inc.

OncoStem

Provista Diagnostics

Thermo Fisher Scientific Inc.

Myriad Genetics, Inc.

Illumina, Inc.

Bio-Rad Laboratories, Inc.

NanoString.

Cepheid

BIOMERIEUX

Exact Sciences Corporation

Biocept, Inc.

Abacus ALS

1 INTRODUCTION 49

1.1 OBJECTIVES OF THE STUDY 49
1.2 MARKET DEFINITION 49
1.3 OVERVIEW OF THE GLOBAL BREAST CANCER DIAGNOSTIC MARKET 49
1.4 CURRENCY AND PRICING 51
1.5 LIMITATIONS 51
1.6 MARKETS COVERED 51

2 MARKET SEGMENTATION 55

2.1 MARKETS COVERED 55
2.2 GEOGRAPHICAL SCOPE 56
2.3 YEARS CONSIDERED FOR THE STUDY 57
2.4 DBMR TRIPOD DATA VALIDATION MODEL 58
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 61
2.6 MULTIVARIATE MODELLING 62
2.7 MARKET END USER COVERAGE GRID 63
2.8 TEST TYPE LIFELINE CURVE 64
2.9 DBMR MARKET POSITION GRID 65
2.10 VENDOR SHARE ANALYSIS 66
2.11 SECONDARY SOURCES 67
2.12 ASSUMPTIONS 67

3 EXECUTIVE SUMMARY 68

4 PREMIUM INSIGHTS 70

4.1 PESTEL ANALYSIS 73
4.2 PORTER'S 5 FORCES 74

5 EPIDEMIOLOGY 75

6 INDUSTRIAL INSIGHTS 76

7 REGULATORY FRAMEWORK 77

8 MARKET OVERVIEW 79

8.1 DRIVERS 81
- 8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH 81
- 8.1.2 INCREASING PREVALENCE OF BREAST CANCER 81
- 8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH 82
- 8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER 82
8.2 RESTRAINTS 83
- 8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS 83
- 8.2.2 HIGH COST OF THE IMAGING SYSTEMS 83
8.3 OPPORTUNITIES 84
- 8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT 84
- 8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS 84
- 8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER 85
8.4 CHALLENGES 85
- 8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 85
- 8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER 86

9 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE 87

9.1 OVERVIEW 88
9.2 IMAGING 91
- 9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES 92
  - 9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM) 93
  - 9.2.1.2 ANALOG MAMMOGRAPHY 93
  - 9.2.1.3 3D BREAST TOMOSYNTHESIS 93
  - 9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT) 93
  - 9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI) 93
  - 9.2.1.6 POSITRON EMISSION MAMMOGRAPHY 93
  - 9.2.1.7 OTHERS 93
- 9.2.2 NON-IONIZING IMAGING TECHNOLOGIES 93
  - 9.2.2.1 OPTICAL IMAGING 94
  - 9.2.2.2 BREAST ULTRASOUND 94
  - 9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING) 94
  - 9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU) 94
  - 9.2.2.5 BREAST THERMOGRAPHY 95
- 9.2.3 BIOPSY 95
  - 9.2.3.1 SURGICAL BIOPSY 96
  - 9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY 96
  - 9.2.3.3 CORE NEEDLE BIOPSY 96
  - 9.2.3.4 IMAGE-GUIDED BIOPSY 96
  - 9.2.3.5 SENTINEL LYMPH NODE BIOPSY 97
- 9.2.4 GENOMIC TEST 97
  - 9.2.4.1 MOLECULAR TESTING 98
    - 9.2.4.1.1 PD-L1 99
    - 9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR) 99
    - 9.2.4.1.3 NTRK GENE FUSIONS 99
    - 9.2.4.1.4 PI3KCA GENE MUTATION 99
  - 9.2.4.2 MAMMAPRINT 99
  - 9.2.4.3 ONCOTYPE DX 99
  - 9.2.4.4 OTHERS 99
9.3 BLOOD TEST 100
9.4 OTHERS 101

10 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY TYPE 102

10.1 OVERVIEW 103
10.2 INVASIVE DUCTAL CARCINOMA 106
10.3 DUCTAL CARCINOMA IN SITU 106
10.4 INFLAMMATORY BREAST CANCER 107
10.5 METASTATIC BREAST CANCER 108

11 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY END USER 109

11.1 OVERVIEW 110
11.2 HOSPITALS 112
11.3 DIAGNOSTICS CENTERS 113
11.4 CLINICS 114
11.5 RESEARCH & ACADEMIC INSTITUTES 114
11.6 OTHERS 115

12 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 117

12.1 OVERVIEW 118
12.2 DIRECT TENDER 121
12.3 RETAIL SALES 121
12.4 OTHERS 122

13 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY REGION 123

13.1 OVERVIEW 124
13.2 NORTH AMERICA 129
- 13.2.1 U.S. 137
- 13.2.2 CANADA 143
- 13.2.3 MEXICO 149
13.3 EUROPE 155
- 13.3.1 GERMANY 164
- 13.3.2 FRANCE 170
- 13.3.3 RUSSIA 176
- 13.3.4 ITALY 182
- 13.3.5 U.K. 188
- 13.3.6 SPAIN 194
- 13.3.7 TURKEY 200
- 13.3.8 NETHERLANDS 206
- 13.3.9 BELGIUM 212
- 13.3.10 SWITZERLAND 218
- 13.3.11 IRELAND 224
- 13.3.12 REST OF EUROPE 230
13.4 ASIA-PACIFIC 231
- 13.4.1 CHINA 240
- 13.4.2 INDIA 246
- 13.4.3 JAPAN 252
- 13.4.4 INDONESIA 258
- 13.4.5 PHILIPPINES 264
- 13.4.6 THAILAND 270
- 13.4.7 AUSTRALIA 276
- 13.4.8 MALAYSIA 282
- 13.4.9 SOUTH KOREA 288
- 13.4.10 SINGAPORE 294
- 13.4.11 REST OF ASIA-PACIFIC 300
13.5 SOUTH AMERICA 301
- 13.5.1 BRAZIL 309
- 13.5.2 ARGENTINA 315
- 13.5.3 REST OF SOUTH AMERICA 321
13.6 MIDDLE EAST AND AFRICA 322
- 13.6.1 EGYPT 331
- 13.6.2 SOUTH AFRICA 337
- 13.6.3 ISRAEL 343
- 13.6.4 SAUDI ARABIA 349
- 13.6.5 UAE 355
- 13.6.6 REST OF MIDDLE EAST AND AFRICA 361

14 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 362

14.1 COMPANY SHARE ANALYSIS: GLOBAL 362
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 363
14.3 COMPANY SHARE ANALYSIS: EUROPE 364
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 365

15 SWOT ANALYSIS 366

16 COMPANY PROFILE 367

16.1 HOLOGIC, INC. 367
- 16.1.1 COMPANY SNAPSHOT 367
- 16.1.2 REVENUE ANALYSIS 367
- 16.1.3 COMPANY SHARE ANALYSIS 368
- 16.1.4 PRODUCT PORTFOLIO 368
- 16.1.5 RECENT DEVELOPMENTS 369
16.2 SIEMENS HEALTHCARE GMBH 370
- 16.2.1 COMPANY SNAPSHOT 370
- 16.2.2 REVENUE ANALYSIS 371
- 16.2.3 COMPANY SHARE ANALYSIS 371
- 16.2.4 PRODUCT PORTFOLIO 372
- 16.2.5 RECENT DEVELOPMENTS 372
16.3 F. HOFFMANN- LA ROCHE LTD 373
- 16.3.1 COMPANY SNAPSHOT 373
- 16.3.2 REVENUE ANALYSIS 373
- 16.3.3 COMPANY SHARE ANALYSIS 374
- 16.3.4 PRODUCT PORTFOLIO 374
- 16.3.5 RECENT DEVELOPMENTS 375
16.4 KONINKLIJKE PHILIPS N.V. 376
- 16.4.1 COMPANY SNAPSHOT 376
- 16.4.2 REVENUE ANALYSIS 376
- 16.4.3 COMPANY SHARE ANALYSIS 377
- 16.4.4 PRODUCT PORTFOLIO 377
- 16.4.5 RECENT DEVELOPMENTS 378
16.5 ABBOTT 379
- 16.5.1 COMPANY SNAPSHOT 379
- 16.5.2 REVENUE ANALYSIS 379
- 16.5.3 COMPANY SHARE ANALYSIS 380
- 16.5.4 PRODUCT PORTFOLIO 380
- 16.5.5 RECENT DEVELOPMENTS 380
16.6 ABACUS ALS 381
- 16.6.1 COMPANY SNAPSHOT 381
- 16.6.2 PRODUCT PORTFOLIO 381
- 16.6.3 RECENT DEVELOPMENTS 381
16.7 BD 382
- 16.7.1 COMPANY SNAPSHOT 382
- 16.7.2 REVENUE ANALYSIS 382
- 16.7.3 COMPANY SHARE ANALYSIS 383
- 16.7.4 PRODUCT PORTFOLIO 383
- 16.7.5 RECENT DEVELOPMENTS 383
16.8 BIOCEPT, INC. 384
- 16.8.1 COMPANY SNAPSHOT 384
- 16.8.2 REVENUE ANALYSIS 384
- 16.8.3 PRODUCT PORTFOLIO 385
- 16.8.4 RECENT DEVELOPMENTS 385
16.9 BIOMERIEUX 386
- 16.9.1 COMPANY SNAPSHOT 386
- 16.9.2 REVENUE ANALYSIS 386
- 16.9.3 PRODUCT PORTFOLIO 387
- 16.9.4 RECENT DEVELOPMENTS 387
16.10 BIO-RAD LABORATORIES, INC. 388
- 16.10.1 COMPANY SNAPSHOT 388
- 16.10.2 REVENUE ANALYSIS 388
- 16.10.3 PRODUCT PORTFOLIO 389
- 16.10.4 RECENT DEVELOPMENT 389
16.11 CEPHEID 390
- 16.11.1 COMPANY SNAPSHOT 390
- 16.11.2 REVENUE ANALYSIS 390
- 16.11.3 PRODUCT PORTFOLIO 391
- 16.11.4 RECENT DEVELOPMENT 391
16.12 EXACT SCIENCES CORPORATION 392
- 16.12.1 COMPANY SNAPSHOT 392
- 16.12.2 REVENUE ANALYSIS 392
- 16.12.3 COMPANY SHARE ANALYSIS 393
- 16.12.4 PRODUCT PORTFOLIO 393
- 16.12.5 RECENT DEVELOPMENTS 394
16.13 FUJIFILM CORPORATION 395
- 16.13.1 COMPANY SNAPSHOT 395
- 16.13.2 REVENUE ANALYSIS 395
- 16.13.3 PRODUCT PORTFOLIO 396
- 16.13.4 RECENT DEVELOPMENT 396
16.14 GENERAL ELECTRIC 397
- 16.14.1 COMPANY SNAPSHOT 397
- 16.14.2 REVENUE ANALYSIS 397
- 16.14.3 PRODUCT PORTFOLIO 398
- 16.14.4 RECENT DEVELOPMENTS 398
16.15 ILLUMINA, INC. 399
- 16.15.1 COMPANY SNAPSHOT 399
- 16.15.2 REVENUE ANALYSIS 399
- 16.15.3 PRODUCT PORTFOLIO 400
- 16.15.4 RECENT DEVELOPMENTS 400
16.16 MYRIAD GENETICS, INC. 401
- 16.16.1 COMPANY SNAPSHOT 401
- 16.16.2 REVENUE ANALYSIS 401
- 16.16.3 PRODUCT PORTFOLIO 402
- 16.16.4 RECENT DEVELOPMENT 402
16.17 NANOSTRING. 403
- 16.17.1 COMPANY SNAPSHOT 403
- 16.17.2 REVENUE ANALYSIS 403
- 16.17.3 PRODUCT PORTFOLIO 404
- 16.17.4 RECENT DEVELOPMENT 404
- 16.17.5 RECENT DEVELOPMENT 404
16.18 ONCOSTEM. 405
- 16.18.1 COMPANY SNAPSHOT 405
- 16.18.2 PRODUCT PORTFOLIO 405
- 16.18.3 RECENT DEVELOPMENT 405
16.19 PROVISTA DIAGNOSTICS. 406
- 16.19.1 COMPANY SNAPSHOT 406
- 16.19.2 PRODUCT PORTFOLIO 406
- 16.19.3 RECENT DEVELOPMENT 406
16.20 THERMO FISHER SCIENTIFIC INC. 407
- 16.20.1 COMPANY SNAPSHOT 407
- 16.20.2 REVENUE ANALYSIS 407
- 16.20.3 PRODUCT PORTFOLIO 408
- 16.20.4 RECENT DEVELOPMENT 408

17 QUESTIONNAIRE 409

18 RELATED REPORTS 412

LIST OF TABLES

TABLE 1 INCIDENCE RATE OF BREAST CANCER (2020) 75
TABLE 2 MORTALITY RATE OF BREAST CANCER (2020) 75
TABLE 3 INCIDENCE OF DUCTAL CARCINOMA IN SITU (DCIS) BREAST CANCER 75
TABLE 4 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 90
TABLE 5 GLOBAL IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 6 GLOBAL IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 91
TABLE 7 GLOBAL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 92
TABLE 8 GLOBAL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 92
TABLE 9 GLOBAL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 94
TABLE 10 GLOBAL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 94
TABLE 11 GLOBAL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 95
TABLE 12 GLOBAL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 96
TABLE 13 GLOBAL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 96
TABLE 14 GLOBAL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 97
TABLE 15 GLOBAL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 98
TABLE 16 GLOBAL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 98
TABLE 17 GLOBAL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 98
TABLE 18 GLOBAL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 99
TABLE 19 GLOBAL BLOOD TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 100
TABLE 20 GLOBAL OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 101
TABLE 21 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 105
TABLE 22 GLOBAL INVASIVE DUCTAL CARCINOMA IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 106
TABLE 23 GLOBAL DUCTAL CARCINOMA IN SITU IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 107
TABLE 24 GLOBAL INFLAMMATORY BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 108
TABLE 25 GLOBAL METASTATIC BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 108
TABLE 26 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 112
TABLE 27 GLOBAL HOSPITALS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 113
TABLE 28 GLOBAL DIAGNOSTIC CENTERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 113
TABLE 29 GLOBAL CLINICS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 114
TABLE 30 GLOBAL RESEARCH AND ACADEMIC INSTITUTES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 115
TABLE 31 GLOBAL OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 116
TABLE 32 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 120
TABLE 33 GLOBAL DIRECT TENDER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 121
TABLE 34 GLOBAL RETAIL SALES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 122
TABLE 35 GLOBAL OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 122
TABLE 36 GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 128
TABLE 37 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 133
TABLE 38 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 133
TABLE 39 NORTH AMERICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 133
TABLE 40 NORTH AMERICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 133
TABLE 41 NORTH AMERICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 134
TABLE 42 NORTH AMERICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 134
TABLE 43 NORTH AMERICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 134
TABLE 44 NORTH AMERICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 134
TABLE 45 NORTH AMERICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 135
TABLE 46 NORTH AMERICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 135
TABLE 47 NORTH AMERICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 135
TABLE 48 NORTH AMERICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 135
TABLE 49 NORTH AMERICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 136
TABLE 50 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 136
TABLE 51 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 136
TABLE 52 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 136
TABLE 53 U.S. BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
TABLE 54 U.S. IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
TABLE 55 U.S. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
TABLE 56 U.S. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 138
TABLE 57 U.S. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 138
TABLE 58 U.S. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 138
TABLE 59 U.S. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 139
TABLE 60 U.S. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 139
TABLE 61 U.S. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 139
TABLE 62 U.S. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 139
TABLE 63 U.S. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 140
TABLE 64 U.S. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 140
TABLE 65 U.S. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 140
TABLE 66 U.S. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 140
TABLE 67 U.S. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 140
TABLE 68 U.S. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 141
TABLE 69 U.S. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 141
TABLE 70 U.S. BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 141
TABLE 71 U.S. BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 141
TABLE 72 U.S. BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 142
TABLE 73 CANADA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
TABLE 74 CANADA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
TABLE 75 CANADA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
TABLE 76 CANADA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 144
TABLE 77 CANADA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 144
TABLE 78 CANADA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 144
TABLE 79 CANADA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 145
TABLE 80 CANADA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 145
TABLE 81 CANADA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 145
TABLE 82 CANADA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 145
TABLE 83 CANADA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 146
TABLE 84 CANADA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 146
TABLE 85 CANADA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 146
TABLE 86 CANADA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 146
TABLE 87 CANADA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 146
TABLE 88 CANADA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 147
TABLE 89 CANADA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 147
TABLE 90 CANADA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 147
TABLE 91 CANADA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 147
TABLE 92 CANADA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 148
TABLE 93 MEXICO BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
TABLE 94 MEXICO IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
TABLE 95 MEXICO IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
TABLE 96 MEXICO IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 150
TABLE 97 MEXICO IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 150
TABLE 98 MEXICO NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 150
TABLE 99 MEXICO NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 151
TABLE 100 MEXICO NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 151
TABLE 101 MEXICO BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 151
TABLE 102 MEXICO BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 151
TABLE 103 MEXICO BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 152
TABLE 104 MEXICO GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 152
TABLE 105 MEXICO GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 152
TABLE 106 MEXICO GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 152
TABLE 107 MEXICO MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 152
TABLE 108 MEXICO MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 153
TABLE 109 MEXICO MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 153
TABLE 110 MEXICO BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 153
TABLE 111 MEXICO BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 153
TABLE 112 MEXICO BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 154
TABLE 113 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 159
TABLE 114 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 159
TABLE 115 EUROPE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 159
TABLE 116 EUROPE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 160
TABLE 117 EUROPE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 160
TABLE 118 EUROPE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 160
TABLE 119 EUROPE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 161
TABLE 120 EUROPE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
TABLE 121 EUROPE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 161
TABLE 122 EUROPE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
TABLE 123 EUROPE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 162
TABLE 124 EUROPE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
TABLE 125 EUROPE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 162
TABLE 126 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 162
TABLE 127 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 163
TABLE 128 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 163
TABLE 129 GERMANY BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
TABLE 130 GERMANY IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
TABLE 131 GERMANY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
TABLE 132 GERMANY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 165
TABLE 133 GERMANY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 165
TABLE 134 GERMANY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 165
TABLE 135 GERMANY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 166
TABLE 136 GERMANY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 166
TABLE 137 GERMANY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 166
TABLE 138 GERMANY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 166
TABLE 139 GERMANY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 167
TABLE 140 GERMANY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 167
TABLE 141 GERMANY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 167
TABLE 142 GERMANY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 167
TABLE 143 GERMANY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 167
TABLE 144 GERMANY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 168
TABLE 145 GERMANY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 168
TABLE 146 GERMANY BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 168
TABLE 147 GERMANY BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 168
TABLE 148 GERMANY BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 169
TABLE 149 FRANCE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
TABLE 150 FRANCE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
TABLE 151 FRANCE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
TABLE 152 FRANCE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 171
TABLE 153 FRANCE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 171
TABLE 154 FRANCE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
TABLE 155 FRANCE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 172
TABLE 156 FRANCE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 172
TABLE 157 FRANCE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 172
TABLE 158 FRANCE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 172
TABLE 159 FRANCE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 173
TABLE 160 FRANCE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 173
TABLE 161 FRANCE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 173
TABLE 162 FRANCE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 173
TABLE 163 FRANCE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 173
TABLE 164 FRANCE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 174
TABLE 165 FRANCE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 174
TABLE 166 FRANCE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 174
TABLE 167 FRANCE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 174
TABLE 168 FRANCE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 175
TABLE 169 RUSSIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 176
TABLE 170 RUSSIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 176
TABLE 171 RUSSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 176
TABLE 172 RUSSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 177
TABLE 173 RUSSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 177
TABLE 174 RUSSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 177
TABLE 175 RUSSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 178
TABLE 176 RUSSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 178
TABLE 177 RUSSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 178
TABLE 178 RUSSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 178
TABLE 179 RUSSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 179
TABLE 180 RUSSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 179
TABLE 181 RUSSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 179
TABLE 182 RUSSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 179
TABLE 183 RUSSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 179
TABLE 184 RUSSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 180
TABLE 185 RUSSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 180
TABLE 186 RUSSIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 180
TABLE 187 RUSSIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 180

TABLE 188 RUSSIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 181
TABLE 189 ITALY BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 182
TABLE 190 ITALY IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 182
TABLE 191 ITALY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 182
TABLE 192 ITALY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 183
TABLE 193 ITALY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 183
TABLE 194 ITALY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 183
TABLE 195 ITALY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 184
TABLE 196 ITALY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 184
TABLE 197 ITALY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 184
TABLE 198 ITALY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 184
TABLE 199 ITALY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 185
TABLE 200 ITALY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 185
TABLE 201 ITALY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 185
TABLE 202 ITALY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 185
TABLE 203 ITALY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 185
TABLE 204 ITALY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 186
TABLE 205 ITALY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 186
TABLE 206 ITALY BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 186
TABLE 207 ITALY BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 186
TABLE 208 ITALY BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 187
TABLE 209 U.K. BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 188
TABLE 210 U.K. IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 188
TABLE 211 U.K. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 188
TABLE 212 U.K. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 189
TABLE 213 U.K. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 189
TABLE 214 U.K. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 189
TABLE 215 U.K. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 190
TABLE 216 U.K. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 190
TABLE 217 U.K. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 190
TABLE 218 U.K. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 190
TABLE 219 U.K. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 191
TABLE 220 U.K. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 191
TABLE 221 U.K. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 191
TABLE 222 U.K. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 191
TABLE 223 U.K. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 191
TABLE 224 U.K. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 192
TABLE 225 U.K. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 192
TABLE 226 U.K. BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 192
TABLE 227 U.K. BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 192
TABLE 228 U.K. BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 193
TABLE 229 SPAIN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 194
TABLE 230 SPAIN IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 194
TABLE 231 SPAIN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 194
TABLE 232 SPAIN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 195
TABLE 233 SPAIN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 195
TABLE 234 SPAIN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 195
TABLE 235 SPAIN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 196
TABLE 236 SPAIN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 196
TABLE 237 SPAIN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 196
TABLE 238 SPAIN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 196
TABLE 239 SPAIN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 197
TABLE 240 SPAIN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 197
TABLE 241 SPAIN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 197
TABLE 242 SPAIN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 197
TABLE 243 SPAIN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 197
TABLE 244 SPAIN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 198
TABLE 245 SPAIN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 198
TABLE 246 SPAIN BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 198
TABLE 247 SPAIN BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 198
TABLE 248 SPAIN BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 199
TABLE 249 TURKEY BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 200
TABLE 250 TURKEY IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 200
TABLE 251 TURKEY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 200
TABLE 252 TURKEY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 201
TABLE 253 TURKEY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 201
TABLE 254 TURKEY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 201
TABLE 255 TURKEY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 202
TABLE 256 TURKEY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 202
TABLE 257 TURKEY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 202
TABLE 258 TURKEY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 202
TABLE 259 TURKEY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 203
TABLE 260 TURKEY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 203
TABLE 261 TURKEY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 203
TABLE 262 TURKEY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 203
TABLE 263 TURKEY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 203
TABLE 264 TURKEY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 204
TABLE 265 TURKEY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 204
TABLE 266 TURKEY BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 204
TABLE 267 TURKEY BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 204
TABLE 268 TURKEY BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 205
TABLE 269 NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 206
TABLE 270 NETHERLANDS IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 206
TABLE 271 NETHERLANDS IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 206
TABLE 272 NETHERLANDS IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 207
TABLE 273 NETHERLANDS IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 207
TABLE 274 NETHERLANDS NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 207
TABLE 275 NETHERLANDS NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 208
TABLE 276 NETHERLANDS NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 208
TABLE 277 NETHERLANDS BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 208
TABLE 278 NETHERLANDS BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 208
TABLE 279 NETHERLANDS BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 209
TABLE 280 NETHERLANDS GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 209
TABLE 281 NETHERLANDS GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 209
TABLE 282 NETHERLANDS GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 209
TABLE 283 NETHERLANDS MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 209
TABLE 284 NETHERLANDS MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 210
TABLE 285 NETHERLANDS MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 210
TABLE 286 NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 210
TABLE 287 NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 210
TABLE 288 NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 211
TABLE 289 BELGIUM BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 212
TABLE 290 BELGIUM IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 212
TABLE 291 BELGIUM IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 212
TABLE 292 BELGIUM IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 213
TABLE 293 BELGIUM IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 213
TABLE 294 BELGIUM NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 213
TABLE 295 BELGIUM NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 214
TABLE 296 BELGIUM NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 214
TABLE 297 BELGIUM BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 214
TABLE 298 BELGIUM BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 214
TABLE 299 BELGIUM BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 215
TABLE 300 BELGIUM GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 215
TABLE 301 BELGIUM GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 215
TABLE 302 BELGIUM GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 215
TABLE 303 BELGIUM MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 215
TABLE 304 BELGIUM MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 216
TABLE 305 BELGIUM MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 216
TABLE 306 BELGIUM BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 216
TABLE 307 BELGIUM BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 216
TABLE 308 BELGIUM BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 217
TABLE 309 SWITZERLAND BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 218
TABLE 310 SWITZERLAND IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 218
TABLE 311 SWITZERLAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 218
TABLE 312 SWITZERLAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 219
TABLE 313 SWITZERLAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 219
TABLE 314 SWITZERLAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 219
TABLE 315 SWITZERLAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 220
TABLE 316 SWITZERLAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 220
TABLE 317 SWITZERLAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 220
TABLE 318 SWITZERLAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 220
TABLE 319 SWITZERLAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 221
TABLE 320 SWITZERLAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 221
TABLE 321 SWITZERLAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 221
TABLE 322 SWITZERLAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 221
TABLE 323 SWITZERLAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 221
TABLE 324 SWITZERLAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 222
TABLE 325 SWITZERLAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 222
TABLE 326 SWITZERLAND BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 222
TABLE 327 SWITZERLAND BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 222
TABLE 328 SWITZERLAND BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 223
TABLE 329 IRELAND BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 224
TABLE 330 IRELAND IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 224
TABLE 331 IRELAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 224
TABLE 332 IRELAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 225
TABLE 333 IRELAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 225
TABLE 334 IRELAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 225
TABLE 335 IRELAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 226
TABLE 336 IRELAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 226
TABLE 337 IRELAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 226
TABLE 338 IRELAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 226

LIST OF FIGURES

FIGURE 1 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION 55
FIGURE 2 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 58
FIGURE 3 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 59
FIGURE 4 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 60
FIGURE 5 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 60
FIGURE 6 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 61
FIGURE 7 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: MARKET END USER COVERAGE GRID 63
FIGURE 8 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 65
FIGURE 9 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 66
FIGURE 10 GLOBAL BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION 69
FIGURE 11 GROWING AWARENESS OF BREAST CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL BREAST CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 70
FIGURE 12 THE IMAGING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BREAST CANCER DIAGNOSTIC MARKET IN 2023 & 2030 70
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BREAST CANCER DIAGNOSTIC MARKET, AND ASIA PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 71
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR GLOBAL BREAST CANCER DIAGNOSTICS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 72
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL BREAST CANCER DIAGNOSTICS MARKET 80
FIGURE 16 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022 88
FIGURE 17 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION) 89
FIGURE 18 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030) 89
FIGURE 19 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE 90
FIGURE 20 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2022 103
FIGURE 21 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2023-2030 (USD MILLION) 104
FIGURE 22 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, CAGR (2023-2030) 104
FIGURE 23 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, LIFELINE CURVE 105
FIGURE 24 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2022 110
FIGURE 25 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION) 111
FIGURE 26 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030) 111
FIGURE 27 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 112
FIGURE 28 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022 118
FIGURE 29 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 119
FIGURE 30 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 119
FIGURE 31 GLOBAL BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 120
FIGURE 32 GLOBAL BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 125
FIGURE 33 GLOBAL BREAST CANCER DIAGNOSTICS MARKET: BY REGION (2022) 126
FIGURE 34 GLOBAL BREAST CANCER DIAGNOSTICS MARKET: BY REGION (2023 & 2030) 126
FIGURE 35 GLOBAL BREAST CANCER DIAGNOSTICS MARKET: BY REGION (2022 & 2030) 127
FIGURE 36 GLOBAL BREAST CANCER DIAGNOSTICS MARKET: BY TEST TYPE (2023-2030) 127
FIGURE 37 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 130
FIGURE 38 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 131
FIGURE 39 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 131
FIGURE 40 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 132
FIGURE 41 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 132
FIGURE 42 EUROPE BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 156
FIGURE 43 EUROPE BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 157
FIGURE 44 EUROPE BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 157
FIGURE 45 EUROPE BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 158
FIGURE 46 EUROPE BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 158
FIGURE 47 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 232
FIGURE 48 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 233
FIGURE 49 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 233
FIGURE 50 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 234
FIGURE 51 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 234
FIGURE 52 SOUTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 302
FIGURE 53 SOUTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 303
FIGURE 54 SOUTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 303
FIGURE 55 SOUTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 304
FIGURE 56 SOUTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 304
FIGURE 57 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 323
FIGURE 58 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 324
FIGURE 59 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 324
FIGURE 60 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 325
FIGURE 61 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 325
FIGURE 62 GLOBAL BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 362
FIGURE 63 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 363
FIGURE 64 EUROPE BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 364
FIGURE 65 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 365